Article
Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones.
Cell research - 1 Jan 2013
Konieczkowski David J, Garraway Levi A
Abstract excerpt
Two recent papers identify KRAS activation as a mechanism of acquired resistance to EGFR blockade in colorectal cancer. In doing so, they suggest that resistance to single-agent EGFR blockade will be unavoidable because these alterations exist as latent subclones within the tumor even prior to the initiation of therapy.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
